HDAC9 and cancer: Moreover, the pleiotropic effects of HDAC inhibition and neurotoxicity of sustained strong inhibition raise the question as to their suitability for treating chronic neurodegenerative disease [49], particularly given the documented adverse side-effects of HDAC inhibitors after short-term therapy in cancer patients [50].